OVERVIEW

The Future of Ibd Management: New Targets, Therapies, and Personalized Approaches Is Organized by Healthcare Made Practical (Hmp) Communications Llc and Will Be Held From Dec 30, 2018 - Dec 30, 2019. This CME Conference has been approved for a maximum of 0.75 AMA PRA Category 1 Credits.

Target Audience:
This Activity Is Intended for Ibd Specialists, Gastroenterologists,gi Fellows, and Other Healthcare Professionals (Internists, Primary Care Physicians, Nurse Practitioners, Physician Assistants, Nurses, Pharmacists, Etc) Involved and/or Interested in the Therapeutic Management of Patients With IDB.

Description:
In Recent Years, Treatment Options for Ibd Have Greatly Expanded With the Advent of New Biologic Agents With Mechanisms of Action That Target Various Aspects of the Inflammatory Process. These Medications Can Enable Mucosal Healing, Slow or Stop Disease Progression, and Eliminate or Reduce the Need for Steroid Use. However, the Need for New Therapies and Improved Clinical Strategies Remains.
Personalized Medicine Will Be Required to Achieve Optimal Outcomes in These Patients. Predictive Factors for Severe Disease Course and Nonresponse to Treatment Have Been Developed Based on Clinical Studies. As More Drug Classes Approved for the Treatment of Ibd Become Available, Clinicians Will Need to Consider Multiple Factors in the Management of Their Ibd Patients to Preempt Nonresponse and Lost Time in Treatment.
In Addition to Anti-tnf Medications, Newer Biologics With Different Mechanisms of Action Have Been Approved—the Anti-α4 Integrins, Vedolizumab and Natalizumab, and the Interleukin (Il)-12/23 Inhibitor, Ustekinumab—that Extend the Options Available to Clinicians Who Treat Patients With Ibd. Several More Medications for the Treatment of Ibd Are in Late-phase Clinical Trials. Clinicians Need to Fully Understand the Mechanisms of Action and Clinical Usefulness of These New and Emerging Treatments for Ibd.
The Goal of This Webcast Is to Provide Gastroenterology Professionals With Expert Guidance on the Selection and Use of Newer Targeted Therapies for Ibd and How to Leverage Implementation Strategies for Optimal Clinical Management and Improved Patient Outcomes. Upon Completion, Learners Should Be Better Able to Critically Evaluate and Interpret These Newer Treatment Targets to Make an Informed, Optimal Therapeutic Judgment in Day-to-day Clinical Practice.

Objectives:
Upon Successful Completion of This Educational Activity, Participants Should Be Better Able to:
• Develop Personalized Treatment Strategies for Patients With Ibd Based on Predictive Factors for Severe Disease Course.
• Identify Molecular Inflammatory Targets of New and Emerging Agents for the Treatment of Ibd.
• Summarize Efficacy and Safety Data for Novel Ibd Targeted Therapies.